JPH10237071A - 新規２−アミノインダン化合物、その製造法、及びそれらを含有する医薬組成物 - Google Patents

新規２−アミノインダン化合物、その製造法、及びそれらを含有する医薬組成物

Info

Publication number
JPH10237071A
JPH10237071A JP10042716A JP4271698A JPH10237071A JP H10237071 A JPH10237071 A JP H10237071A JP 10042716 A JP10042716 A JP 10042716A JP 4271698 A JP4271698 A JP 4271698A JP H10237071 A JPH10237071 A JP H10237071A
Authority
JP
Japan
Prior art keywords
piperidine
amino
dihydro
benzodioxin
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP10042716A
Other languages
English (en)
Japanese (ja)
Other versions
JPH10237071A5 (https=
Inventor
Jean-Louis Peglion
ジャン−ルイ・ペリヨン
Bertrand Goument
ベルトラン・グマン
Mark Millan
マルク・ミラン
Alain Gobert
アラン・ゴベール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADIR SARL
Original Assignee
ADIR SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADIR SARL filed Critical ADIR SARL
Publication of JPH10237071A publication Critical patent/JPH10237071A/ja
Publication of JPH10237071A5 publication Critical patent/JPH10237071A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
JP10042716A 1997-02-27 1998-02-25 新規２−アミノインダン化合物、その製造法、及びそれらを含有する医薬組成物 Pending JPH10237071A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9702360A FR2760014B1 (fr) 1997-02-27 1997-02-27 Nouveaux composes de 2-amino indane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR9702360 1997-02-27

Publications (2)

Publication Number Publication Date
JPH10237071A true JPH10237071A (ja) 1998-09-08
JPH10237071A5 JPH10237071A5 (https=) 2005-08-04

Family

ID=9504253

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10042716A Pending JPH10237071A (ja) 1997-02-27 1998-02-25 新規２−アミノインダン化合物、その製造法、及びそれらを含有する医薬組成物

Country Status (18)

Country Link
US (1) US5968954A (https=)
EP (1) EP0861837B1 (https=)
JP (1) JPH10237071A (https=)
CN (1) CN1090627C (https=)
AT (1) ATE265451T1 (https=)
AU (1) AU725756B2 (https=)
BR (1) BR9800763A (https=)
CA (1) CA2231025C (https=)
DE (1) DE69823411T2 (https=)
DK (1) DK0861837T3 (https=)
ES (1) ES2219853T3 (https=)
FR (1) FR2760014B1 (https=)
HU (1) HU224312B1 (https=)
NO (1) NO314307B1 (https=)
NZ (1) NZ329853A (https=)
PL (1) PL190240B1 (https=)
PT (1) PT861837E (https=)
ZA (1) ZA981680B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002534521A (ja) * 1999-01-12 2002-10-15 ビーエーエスエフ アクチェンゲゼルシャフト ドーパミン−３−レセプター親和性を有するトリアゾール化合物
WO2006062063A1 (ja) * 2004-12-08 2006-06-15 Astellas Pharma Inc. ピペリジン誘導体及びその製造法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0103650D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic heterocyclic compounds
KR20080079341A (ko) * 2001-01-16 2008-08-29 아스트라제네카 아베 치료용 헤테로시클릭 화합물
ES2323451T7 (es) 2001-07-20 2011-08-01 Psychogenics Inc. Tratamiento para el trastorno de hiperactividad con deficit de atencion.
JP2005343790A (ja) * 2002-05-31 2005-12-15 Ajinomoto Co Inc カルシウムチャネル拮抗薬を含有する医薬組成物
US20050165025A1 (en) * 2004-01-22 2005-07-28 Recordati Ireland Ltd. Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists
UY29892A1 (es) * 2005-11-04 2007-06-29 Astrazeneca Ab Nuevos derivados de cromano, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9318431D0 (en) * 1993-09-06 1993-10-20 Boots Co Plc Therapeutic agents
FR2734819B1 (fr) * 1995-05-31 1997-07-04 Adir Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002534521A (ja) * 1999-01-12 2002-10-15 ビーエーエスエフ アクチェンゲゼルシャフト ドーパミン−３−レセプター親和性を有するトリアゾール化合物
WO2006062063A1 (ja) * 2004-12-08 2006-06-15 Astellas Pharma Inc. ピペリジン誘導体及びその製造法

Also Published As

Publication number Publication date
FR2760014A1 (fr) 1998-08-28
NO980803D0 (no) 1998-02-26
CN1090627C (zh) 2002-09-11
DE69823411D1 (de) 2004-06-03
HU9800422D0 (en) 1998-04-28
PT861837E (pt) 2004-07-30
BR9800763A (pt) 1999-12-07
ZA981680B (en) 1998-09-04
DK0861837T3 (da) 2004-08-16
US5968954A (en) 1999-10-19
CA2231025C (fr) 2003-09-16
ES2219853T3 (es) 2004-12-01
AU725756B2 (en) 2000-10-19
CN1194983A (zh) 1998-10-07
HUP9800422A1 (hu) 1999-12-28
EP0861837B1 (fr) 2004-04-28
EP0861837A1 (fr) 1998-09-02
HK1014945A1 (en) 1999-10-08
NO980803L (no) 1998-08-28
FR2760014B1 (fr) 1999-04-09
ATE265451T1 (de) 2004-05-15
NZ329853A (en) 1999-01-28
HU224312B1 (hu) 2005-07-28
DE69823411T2 (de) 2005-02-17
PL190240B1 (pl) 2005-11-30
PL324982A1 (en) 1998-08-31
AU5635998A (en) 1998-09-03
CA2231025A1 (fr) 1998-08-27
NO314307B1 (no) 2003-03-03

Similar Documents

Publication Publication Date Title
US5965575A (en) N-aryl piperidine compounds as 5HT1B antagonists
AU2010290871B2 (en) Chromone derivatives, a process for their preparation and their therapeutic applications
KR20010024077A (ko) 치환된 크로만 유도체
JPH10237071A (ja) 新規２−アミノインダン化合物、その製造法、及びそれらを含有する医薬組成物
US6153625A (en) Indan-1-ol compounds
EP1613594B1 (en) 4-(2-phenylsulfanyl-phenyl)-1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors
CA2485537A1 (en) Novel compounds, their use and preparation
JPH11158179A (ja) 新規インダノール化合物、それらの製法及びそれらを含む医薬組成物
JP2011026319A (ja) 新規クロメン化合物、その製造方法、およびそれを含有する医薬組成物
JP4042566B2 (ja) ピペリジン化合物およびその医薬用途
HK1014945B (en) 2-aminoindan compounds, a process for their preparation and pharmaceutical compositions containing them
HK1014954B (en) New n-arylpiperidine compounds, a process for their preparation and pharmaceutical compositions containing them
KR100753905B1 (ko) Ｎ-치환된-1ｈ-퀴놀린-2,4-디온 화합물, 이의 제조 방법 및이를 포함하는 약학적 조성물
PL190924B1 (pl) Pochodne indolu i 2,3 - dihydroindolu, kompozycja farmaceutyczna oraz ich zastosowanie
JP2010534705A (ja) Ｈ１受容体のアンタゴニストとして有用なスピロ化合物
CZ2000947A3 (cs) Substituované chromanové deriváty

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080819

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090210